HALO News and Press, Halozyme Therapeutics Inc. From 08/02/22

Positive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq® with ENHANZE® in Advanced Non-Small Cell Lung Cancer PR Newswire Subcutaneous formulation with ENHANZE ® reduced treatment time to 3-8 minutes...

We once again made Avid Bioservices a large position during the quarter. Unlike most biotech stocks, Avid is a real business, not a binary bet on whether or not a drug will meet its hoped-for end state. At the prices we were buying CDMO, the stock was perhaps 3 or 4 years away fro...

For Q2 2022 Class A interests in Laughing Water Capital returned approximately -19.4%, bringing our year to date returns to approximately -29.5%. We are consciously choosing to accept greater volatility in exchange for the potential to realize greater long-term returns. I believe ...

Halozyme to Report Second Quarter 2022 Financial and Operating Results PR Newswire SAN DIEGO , July 26, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2022 financial and oper...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks have suffered significant setbacks during the first half of the year. Investors had little appetite for innovation-driven companies, seeking safe haven in more traditional stocks delivering steady profits...

Halozyme (HALO) has been the top stock on our watch list for a few weeks now, and while it’s not immune to the market’s wiggles, the stock has actually been rounding out a big launching pad as the indexes implode, observes Mike Cintolo, editor of Cabot Growth Investor. For fur...

Danish biotech firm Genmab A/S (GMAB) said on Thursday it had begun a new arbitration and was seeking an award of $405M under its license agreement with Johnson & Johnson's (JNJ) unit Janssen Biotech for cancer drug, Darzalex. Genmab is locked in a legal battle with JNJ ove...

Halozyme to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference PR Newswire SAN DIEGO , June 8, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley , president and ch...

Halozyme Therapeutics (NASDAQ:HALO) has launched its oral testosterone therapy Tlando. The drug was approved by the U.S. FDA on March 28. Tlando marks Halozyme's second hormone replacement therapy. Xyosted, which is given weekly via subcutaneous auto-injector, was approved in 2018. See why Se...

Halozyme Announces Commercial Launch of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy PR Newswire SAN DIEGO , June 7, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the commercial laun...